PRO_SELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors
about
Increasing the structural coverage of tuberculosis drug targetsDecoys for dockingBinding site characteristics in structure-based virtual screening: evaluation of current docking tools.Novel inhibitors of anthrax edema factor.From laptop to benchtop to bedside: structure-based drug design on protein targets.Fragment-based screening by protein crystallography: successes and pitfalls.CSAR benchmark exercise of 2010: combined evaluation across all submitted scoring functions.Synthesis, structure, and biological activity of novel heterocyclic sulfonyl-carboximidamides.Fragment oriented molecular shapesNeurobiological applications of small molecule screening.Docking, virtual high throughput screening and in silico fragment-based drug designRole of computer-aided drug design in modern drug discovery.Designing the molecular future.Fragment-based screening by biochemical assays: Systematic feasibility studies with trypsin and MMP12.Fragment screening by biochemical assay.A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineeringCombining ligand-based and structure-based drug design in the virtual screening arenaBehavior of 2-iminothiazolidin-4-one with different reagents
P2860
Q27644314-ACFA7E11-BB9C-4274-928C-347B99B7044EQ30350781-C26737A8-5227-4FEA-8A4F-A7C3C9A3A41DQ31135121-790A9898-3E8E-4A6D-A5BD-DA79844DA21FQ33351165-66EF7C77-D6D4-4629-B404-ED3EFD5B30C7Q34153589-92F5268C-DD96-4662-AED3-BA41C2CF6DBBQ34314898-AF310F6D-00F0-44A4-9E30-39FFC444C3FEQ35263970-B0A1BAEC-0411-4551-A806-F8BEA2A6E516Q35828129-1E22FB52-AA28-4FFE-88AD-574591DA5D1BQ36889078-10023DE7-DB62-4CE7-9A11-2081C2CC134DQ37151213-20A58C05-6796-4FF8-8A9C-BB21DD5D4E2CQ37296002-5996AF8E-FCEF-43D4-B221-39621AE665B1Q38553677-3628E2E7-B8B7-44D6-BA95-D4AE75E29BDFQ39681302-94D1A0CF-585E-48C4-8C4C-4D8870F0E031Q42882505-7FD6A7AD-0C80-4268-9674-D9109753ED7FQ53591810-1247CB73-8000-4DAB-ACF8-55FBD9C3A620Q56888917-9C9A15D1-9B4C-41A6-8DB2-DEA9494E12AAQ56979676-E6F2CB87-D9A7-485A-B56A-5AAA3D671567Q57985548-B39BA963-5033-4C61-BAFB-4DDDE1BEA521
P2860
PRO_SELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
PRO_SELECT: combining structur ...... selective factor Xa inhibitors
@ast
PRO_SELECT: combining structur ...... selective factor Xa inhibitors
@en
PRO_SELECT: combining structur ...... selective factor Xa inhibitors
@nl
type
label
PRO_SELECT: combining structur ...... selective factor Xa inhibitors
@ast
PRO_SELECT: combining structur ...... selective factor Xa inhibitors
@en
PRO_SELECT: combining structur ...... selective factor Xa inhibitors
@nl
prefLabel
PRO_SELECT: combining structur ...... selective factor Xa inhibitors
@ast
PRO_SELECT: combining structur ...... selective factor Xa inhibitors
@en
PRO_SELECT: combining structur ...... selective factor Xa inhibitors
@nl
P2093
P356
P1476
PRO_SELECT: combining structur ...... selective factor Xa inhibitors
@en
P2093
Andrew D Rimmer
Bohdan Waszkowycz
Chris W Murray
Jacqui Mahler
John W Liebeschuetz
Jonathan M E Roscoe
Kay Wilkinson
Pauline M Welsh
Phillip J Morgan
P304
P356
10.1021/JM010944E
P407
P50
P577
2002-03-01T00:00:00Z